Clifford J. Rosen
Maine Medical Center
717 Papers
6.3K Citations
Clifford J. Rosen is an academic researcher from Maine Medical Center. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 111, co-authored 655 publications. Previous affiliations of Clifford J. Rosen include Veterans Health Administration & Thomas Jefferson University.
Chat about Author
Papers
Screening calcaneal ultrasound and risk factors for osteoporosis among lesbians and heterosexual women.
Christine L. Patton,Peter S. Millard,Cathy R. Kessenich,Deborah Storm,Elizabeth Kinnicutt,Clifford J. Rosen +5 more
TL;DR: Antidepressant use in both populations was associated with a significant reduction in calcaneal bone mass, and studies are needed to define the relationship of depression and its treatment to bone mineral density and the future risk of osteoporosis.
9
IGF-1 is associated with estimated bone strength in anorexia nervosa.
Pouneh K. Fazeli,Pouneh K. Fazeli,Alexander T. Faje,Erinne Meenaghan,Stephen T. Russell,Megi Resulaj,Hang Lee,Clifford J. Rosen,Mary L. Bouxsein,Mary L. Bouxsein,Anne Klibanski +10 more
TL;DR: IGF-1 is strongly associated with estimated bone strength in the radius and tibia in women with anorexia nervosa and further studies are needed to assess whether treatment with recombinant human IGF-1 will further improve bone strength and reduce fracture risk in this population.
9
Racial differences in bone loss and relation to menopause among HIV-infected and uninfected women
TL;DR: Determining the extent to which the effect of HIV on fracture risk varies by race will be crucial to identify HIV-infected women at greatest risk for osteoporotic fracture, particularly as they enter menopause.
9
Vignettes in osteoporosis: a road map to successful therapeutics.
TL;DR: Five common clinical scenarios encountered in the practice of osteoporosis medicine are described and various road maps that could lead to successful therapy are described.
9
European Medicines Agency must take account of cardiovascular harm associated with degludec insulin
TL;DR: Degludec insulin (Tresiba), Novo Nordisk’s novel analogue, may be viewed in this context as a novel analogue of insulin, and concerns about its marketing led to a letter to the EMA.
9